We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.13 | 1.16% | 98.86 | 99.19 | 98.54 | 98.60 | 1,159,699 | 23:06:40 |
From May 2019 to May 2024
By Donato Paolo Mancini
The U.S. Food and Drug Administration approved Friday the combined use of Novartis's (NOVN.EB) Tafinlar and Mekinist for the treatment of a type of thyroid cancer.
The new use is for the treatment of a genetic variant of anaplastic thyroid cancer that cannot be removed by surgery or has become metastatic, the regulator said.
Both drugs are approved for use, both in combination and individually, for the treatment of a type of melanoma. In combination, they're also used to treat a type of metastatic lung cancer. All indications, including last week's, are for cancers that are mutation-positive to BRAF V600E, an abnormal gene.
Novartis said last month that first-quarter sales of Tafinlar and Mekinist grew 33% to $267 million.
The company's oncology division, long affected by generic price erosion of its former blockbuster Gleevec/Glivec, was helped to swing to a profit by the two drugs.
Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com
(END) Dow Jones Newswires
May 07, 2018 08:34 ET (12:34 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
